Current Pharmacologic Approaches in Painful Bladder Research: An Update
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
The symptoms of interstitial cystitis (IC)/bladder pain syndrome (BPS) may have multiple causes and involve many contributing factors. Traditional treatments (intravesical instillations) have had a primary focus on the bladder as origin of symptoms without adequately considering the potential influence of other local (pelvic) or systemic factors. Systemic pharmacological treatments have had modest success. A contributing factor to the low efficacy is the lack of phenotyping the patients. Individualized treatment based on is desirable, but further phenotype categorization is needed. There seems to be general agreement that IC is a unique disease and that BPS is a syndrome with multiple pathophysiologies, but this has so far not been not been well reflected in preclinical research with the aim of finding new pharmacological treatments. Current research approaches, including anti-nerve growth factor treatment, anti-tumor necrosis factor-α treatment, activation of SHIP1 (AQX-1125), and P2X3 receptor antagonists, and α1-adrenoceptor antagonists are potential systemic treatments, implying that not only the bladder is exposed to the administered drug, which may be beneficial if the IC/BPS is a bladder manifestation of a systemic disease, or negative (adverse effects) if it is a local bladder condition. Local treatment approaches such as the antagonism of Toll-like receptors (which still is only experimental) and intravesical liposomes (with positive proof-of-concept), may have the advantages of a low number of systemic adverse effects, but cannot be expected to have effects on symptoms generated outside the bladder. Assessment of which of the treatment approaches discussed in this review that can be developed into useful therapies requires further studies.
Abstract
The symptoms of interstitial cystitis (IC)/bladder pain syndrome (BPS) may have multiple causes and involve many contributing factors. Traditional treatments (intravesical instillations) have had a primary focus on the bladder as origin of symptoms without adequately considering the potential influence of other local (pelvic) or systemic factors. Systemic pharmacological treatments have had modest success. A contributing factor to the low efficacy is the lack of phenotyping the patients. Individualized treatment based on is desirable, but further phenotype categorization is needed. There seems to be general agreement that IC is a unique disease and that BPS is a syndrome with multiple pathophysiologies, but this has so far not been not been well reflected in preclinical research with the aim of finding new pharmacological treatments. Current research approaches, including anti-nerve growth factor treatment, anti-tumor necrosis factor-α treatment, activation of SHIP1 (AQX-1125), and P2X3 receptor antagonists, and α1-adrenoceptor antagonists are potential systemic treatments, implying that not only the bladder is exposed to the administered drug, which may be beneficial if the IC/BPS is a bladder manifestation of a systemic disease, or negative (adverse effects) if it is a local bladder condition. Local treatment approaches such as the antagonism of Toll-like receptors (which still is only experimental) and intravesical liposomes (with positive proof-of-concept), may have the advantages of a low number of systemic adverse effects, but cannot be expected to have effects on symptoms generated outside the bladder. Assessment of which of the treatment approaches discussed in this review that can be developed into useful therapies requires further studies.
참고문헌 (61)
- "The Empereror Has No Clothes. Lecture AUA, 2017" (2007)[URL]
- Ochodnicky P, "Neurotrophins as regulators of urinary bladder function", Nat Rev Urol, 9, pp.628~637 (2012)
- Lowe EM, "Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis", Br J Urol, 79, pp.572~577 (1997)
- Okragly AJ, "Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients", J Urol, 161, pp.438~441 (1999)
- Qu HC, "Urinary nerve growth factor could be a biomarker for interstitial cystitis", painful bladder syndrome: a meta-analysis, 2014, pp.9, e106321~
- Evans RJ, "Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis", J Urol, 185, pp.1716~1721 (2011)
- Brown MT, "Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial", J Pain, 13, pp.790~798 (2012)
- Chen J, "Efficacy and safety of tanezumab on osteoarthritis knee and hip pains : a meta-analysis of randomized controlled trials", Pain Med, 18, pp.374~385 (2017)
- Sanga P, "Long-term safety and efficacy of fulranumab in patients with moderate-to-severe osteoarthritis pain: a phase ii randomized, doubleblind, placebo-controlled extension study", Arthritis Rheumatol, 69, pp.763~773 (2017)
- Wang H, "Fulranumab in patients with interstitial cystitis", bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study, 2017, pp.17, 2~
- Majima T, "Effect of intravesical liposome-based nerve growth factor antisense therapy on bladder overactivity and nociception in a rat model of cystitis induced by hydrogen peroxide", Hum Gene Ther, 28, pp.598~609 (2017)
- Tyagi P, "Intravesical liposome therapy for interstitial cystitis", Int J Urol, 24, pp.262~271 (2017)
- Tracey D, "Tumor necrosis factor antagonist mechanisms of action : a comprehensive review", Pharmacol Ther, 117, pp.244~279 (2008)
- Croft M, "TNF superfamily in inflammatory disease : translating basic insights", Trends Immunol, 33, pp.144~152 (2012)
- Croft M, "Clinical targeting of the TNF and TNFR superfamilies", Nat Rev Drug Discov, 12, pp.147~168 (2013)
- Ogawa T, "CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis", J Urol, 183, pp.1206~1212 (2010)
- Bosch PC, "Examination of the significant placebo effect in the treatment of interstitial cystitis", bladder pain syndrome, 2014, pp.84, 321~326
- Li P, "Drugs for autoimmune inflammatory diseases : from small molecule compounds to anti-TNF biologics", Front Pharmacol, 8, pp.460~ (2017)
- van de Merwe JP, "Interstitial cystitis and systemic autoimmune diseases", Nat Clin Pract Urol, 4, pp.484~491 (2007)
- van de Merwe JP, "Diagnostic criteria, classification, and nomenclature for painful bladder syndrome", interstitial cystitis: an ESSIC proposal, 2008, pp.53, 60~67
- Homma Y, "Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015", Int J Urol, 23, pp.542~549 (2016)
- O’Neill LA, "The history of Toll-like receptors - redefining innate immunity", Nat Rev Immunol, 13, pp.453~460 (2013)
- Liu T, "Emerging role of Toll-like receptors in the control of pain and itch", Neurosci Bull, 28, pp.131~144 (2012)
- Nicotra L, "Toll-like receptors in chronic pain", Exp Neurol, 234, pp.316~329 (2012)
- Ichihara K, "Toll-like receptor 7 is overexpressed in the bladder of Hunner-type interstitial cystitis, and its activation in the mouse bladder can induce cystitis and bladder pain", Pain, 158, pp.1538~1545 (2017)
- Stenton GR, "Characterization of AQX-1125, a small-molecule SHIP1 activator:Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo", Br J Pharmacol, 168, pp.1506~1518 (2013)
- Condé C, "Enzymatic and non-enzymatic activities of SHIP-1 in signal transduction and cancer", Biochem Pharmacol, 82, pp.1320~1334 (2011)
- Kerr WG, "Inhibitor and activator : dual functions for SHIP in immunity and cancer", Ann N Y Acad Sci, 1217, pp.1~17 (2011)
- Stenton GR, "Characterization of AQX-1125, a small-molecule SHIP1 activator:Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo", Br J Pharmacol, 168, pp.1519~1529 (2013)
- Leaker BR, "The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma", Clin Exp Allergy, 44, pp.1146~1153 (2014)
- Nickel JC, "A phase II study of the efficacy and safety of the novel oral SHIP1 activator AQX-1125 in subjects with moderate to severe interstitial cystitis", bladder pain syndrome, 2016, pp.196, 747~754
- Wang EC, "ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells", J Clin Invest, 115, pp.2412~2422 (2005)
- Cockayne DA, "Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice", Nature, 407, pp.1011~1015 (2000)
- Sun Y, "Effects of dimethyl sulphoxide and heparin on stretch-activated ATP release by bladder urothelial cells from patients with interstitial cystitis", BJU Int, 90, pp.381~385 (2002)
- Sun Y, "Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis", J Urol, 166, pp.1951~1956 (2001)
- Sun Y, "Up-regulation of P2X3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis", J Urol, 171, pp.448~452 (2004)
- Sun Y, "Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis", Am J Physiol Cell Physiol, 290, pp.C27~C34 (2006)
- Abdulqawi R, "P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2study", Lancet, 385, pp.1198~1205 (2015)
- Moldwin R, "A phase 2 study in women with interstitial cystitis", bladder pain syndrome (IC, 45th International Continence Society (ICS) Annual Meeting, pp.2015[DOI]
- Mailis-Gagnon A, "Abnormal contralateral pain responses from an intradermal injection of phenylephrine in a subset of patients with complex regional pain syndrome(CRPS)", Pain, 111, pp.378~384 (2004)
- Chalaye P, "Comparing pain modulation and autonomic responses in fibromyalgia and irritable bowel syndrome patients", Clin J Pain, 28, pp.519~526 (2012)
- Drummond PD, "Reflex sympathetic dystrophy:the significance of differing plasma catecholamine concentrations in affected and unaffected limbs", Brain, 114(Pt 5), pp.2025~2036 (1991)
- Galloway NT, "Interstitial cystitis or reflex sympathetic dystrophy of the bladder?", Semin Urol, 9, pp.148~153 (1991)
- Torebjörk E, "Noradrenaline-evoked pain in neuralgia", Pain, 63, pp.11~20 (1995)
- Chémali KR, "Alpha-adrenergic supersensitivity of the sudomotor nerve in complex regional pain syndrome", Ann Neurol, 49, pp.453~459 (2001)
- Stein PC, "Elevated urinary norepinephrine in interstitial cystitis", Urology, 53, pp.1140~1143 (1999)
- Charrua A, "Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome", interstitial cystitis? A clinical and experimental study, 2015, pp.34, 489~496
- Chelimsky G, "Autonomic testing of women with interstitial cystitis", bladder pain syndrome, 2014, pp.24, 161~166
- Shir Y, "Effects of sympathectomy in a model of causalgiform pain produced by partial sciatic nerve injury in rats", Pain, 45, pp.309~320 (1991)
- Chung K, "Sprouting sympathetic fibers form synaptic varicosities in the dorsal root ganglion of the rat with neuropathic injury", Brain Res, 751, pp.275~280 (1997)
- Yen LD, "Sympathetic sprouting and changes in nociceptive sensory innervation in the glabrous skin of the rat hind paw following partial peripheral nerve injury", J Comp Neurol, 495, pp.679~690 (2006)
- Longo G, "Sympathetic fiber sprouting in inflamed joints and adjacent skin contributes to painrelated behavior in arthritis", J Neurosci, 33, pp.10066~10074 (2013)
- Matos R, "Bladder pain induced by prolonged peripheral alpha 1A adrenoceptor stimulation involves the enhancement of transient receptor potential vanilloid 1 activity and an increase of urothelial adenosine triphosphate release", Acta Physiol(Oxf), 218, pp.265~275 (2016)
- Yunliang Gao, "The role of C-fibers in the development of chronic psychological stress induced enhanced bladder sensations and nociceptive responses: A multidisciplinary approach to the study of urologic chronic pelvic pain syndrome (MAPP) research network study", Neurourology and Urodynamics (2017), Wiley-Blackwell[DOI]
- Sanford MT, "The role of environmental stress on lower urinary tract symptoms", Curr Opin Urol, 27, pp.268~273 (2017)
- Wang Z, "Effects of water avoidance stress on peripheral and central responses during bladder filling in the rat: a multidisciplinary approach to the study of urologic chronic pelvic pain syndrome (MAPP) research network study", PLoS One, 12, pp.e0182976~ (2017)
- Matos R, "The water avoidance stress induces bladder pain due to a prolonged alpha1A adrenoceptor stimulation", Naunyn Schmiedebergs Arch Pharmacol, 390, pp.839~844 (2017)
- Cortesi R, "Liposomes, micelles and microemulsions as new delivery systems for cytotoxic alkaloids", Pharm Sci Technolo Today, 2, pp.288~298 (1999)
- Chuang YC, "Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis", painful bladder syndrome, 2009, pp.182, 1393~1400
- Lee WC, "Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome", Kaohsiung J Med Sci, 27, pp.437~440 (2011)
- Peters KM, "Liposomal bladder instillations for IC", BPS : an open-label clinical evaluation, 2014, pp.46, 2291~2295